Latest Information Update: 24 Jan 2013
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Sep 2006 Discontinued - Phase-I for Thrombosis in Europe (unspecified route)
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
- 07 Feb 2001 New profile